Evidence
J Gastrointestin Liver Dis. 2024 Mar 29;33(1):7-10. doi: 10.15403/jgld-5268.
ABSTRACT
Patients with chronic liver diseases (CLD) were considered to be in peril during the initial stages of the Coronavirus disease (Covid-19) pandemic. Progression of the course of the pandemic, however indicated that risk of severe disease and mortality differed, based on the cause of the hepatic disease. Patients suffering from Alcoholic liver disease or liver cirrhosis were confirmed to be at an increased risk by numerous studies, while that was not the case for HBV affected individuals and liver transplant recipients. The grade of liver fibrosis seemed to be the decisive factor for the severity of Covid-19 infection in the case of HCV infected individuals. Results are conflicting in the case of patients with metabolic- associated steatotic liver disease (MASLD) and insufficient in those with autoimmune liver disease.
PMID:38554411 | DOI:10.15403/jgld-5268
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
COVID-19 in Individuals with Chronic Liver Diseases
🌐 90 Days
VR Related Evidence Matrix
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Occult liver disease: a multinational perspective
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Therapeutic potential of oleanolic acid in liver diseases
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Inflammatory liver diseases and susceptibility to sepsis
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- The double roles of T cell-mediated immune response in the progression of MASLD
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Associations of severe liver diseases with cataract using data from UK Biobank: a prospective cohort study
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Apathetic Graves' disease with severe hepatic and renal dysfunction induced by COVID-19 infection: Case report and literature review
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Metabolic disease and the liver: A review
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead
- The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Time trends in liver-related mortality in people with and without diabetes: Results from a population based study
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Severe Acute Liver Injury: First Manifestation of Systemic Lupus Erythematosus
- The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Hepatitis B virus infection status and clinical characteristics in patients with rheumatoid arthritis
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Interleukins in liver disease treatment
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
Evidence Blueprint
COVID-19 in Individuals with Chronic Liver Diseases
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
COVID-19 in Individuals with Chronic Liver Diseases
🌐 365 Days
VR Related Evidence Matrix
- Statins are associated with a decreased risk of severe liver disease in individuals with non-cirrhotic chronic liver disease
- Influence of chronic liver diseases on the course and outcome of COVID-19
- Investigating the correlation between COVID-19 and the progression of chronic liver disease
- Mortality from chronic liver disease: Recent trends and impact of the COVID-19 pandemic
- Liver disease during the pandemic of COVID-19 infection: prediction of the course and tactics of management: A review
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Occult liver disease: a multinational perspective
- Sarcopenia in chronic liver diseases
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection
- Therapeutic potential of oleanolic acid in liver diseases
- Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
- Unconjugated hyperbilirubinemia may exacerbate certain underlying chronic liver diseases
- Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease
- COVID-19-induced liver injury in infants, children, and adolescents
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Gut Mycobiota Changes in Liver Diseases: a Systematic Review
- Inflammatory liver diseases and susceptibility to sepsis
- Impacts of gut microbiota alteration on age-related chronic liver diseases
- Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study
- Hormone action and liver disease, a complex interplay
- Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- Corrected and republished from: Metabolic associated liver disease
- Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- How non-alcoholic fatty liver disease and cirrhosis affect the heart
- Alcoholic liver disease - 2023
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Fatty liver and celiac disease: Why worry?
- The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease
- Portal vein congestion index in patients with and without chronic liver disease
- Trends of Chronic Liver Disease in a Tertiary Care Centre in the Eastern Part of India: A Retrospective Study
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
- The double roles of T cell-mediated immune response in the progression of MASLD
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- How to identify at-risk NAFLD in the primary care setting
- Associations of severe liver diseases with cataract using data from UK Biobank: a prospective cohort study
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study
- Seroprevalence of hepatitis E virus in patients with chronic liver disease
- Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
- Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality